Larotrectinib (Vitrakvi)

Abstract


 CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
 The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
 This review assesses larotrectinib (Vitrakvi); 25 mg and 100 mg capsules (as larotrectinib sulphate) and 20 mg/mL oral solution (as larotrectinib sulphate).
 Indication: For the treatment of adult and pediatric patients with solid tumours that:
 
 have an NTRK gene fusion without a known acquired resistance mutation
 are metastatic or where surgical resection is likely to result in severe morbidity
 have no satisfactory treatment options